298 related articles for article (PubMed ID: 34232981)
1. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
3. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY
Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904
[No Abstract] [Full Text] [Related]
4. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
5. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
6. Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Oya S; Ozawa H; Maehiro Y; Nakamura T; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Leuk Res; 2023 Jul; 130():107313. PubMed ID: 37207502
[No Abstract] [Full Text] [Related]
7. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
[TBL] [Abstract][Full Text] [Related]
9. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
10. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
11. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
[TBL] [Abstract][Full Text] [Related]
12. Can we selectively target AML stem cells?
Jordan CT
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
14. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
15. [The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Ai H; Mi RH; Chen L; Ji X; Yin QS; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):956-959. PubMed ID: 36709189
[No Abstract] [Full Text] [Related]
16. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
17. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
19. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 inhibition in AML: an unexpected bonus?
Konopleva M; Letai A
Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
